NY-IFF
29.2.2024 22:16:30 CET | Business Wire | Press release
IFF (NYSE: IFF)—a world leader in food and beverage, home and personal care, and health—has been named the top American Company for gender equality and tenth globally by Equileap, a leading organization providing data and insights on gender equality in the corporate sector.
In its seventh annual Gender Equality Global Report & Ranking, Equileap provides a status update on gender equality in the corporate world, evaluating 19 different criteria that range from the gender pay gap and female representation at all corporate levels to parental leave and anti-sexual harassment policies. The research examined 3,795 companies, representing 103 million employees globally, that are listed on a major index or in one of 27 developed markets.
“We’re very proud of this recognition by Equileap—the largest provider of gender data to the investor community—which highlights the progress we’ve made and the deliberate actions we’ve taken to achieve gender equality for IFFers,” said Deb Borg, IFF chief human resources, diversity & inclusion, and communications officer. “This progress belongs to all of us who have imagined a more inclusive future and acted on that inspiration. We believe that embracing the uniqueness of our diverse workforce unleashes innovative possibilities at the intersection of science and creativity.”
“By intentionally considering inclusion in how we make decisions, build programs, implement our talent processes and create policies, we ask ourselves how we are eliminating barriers to access so that fair outcomes can flourish at IFF,” said Erik Fyrwald, IFF CEO. “We know that a more diverse and inclusive IFF benefits our people, customers, industry, and communities.”
IFF’s recognition as the leader in Gender Equality highlights the following progress in 2023:
- Continued progress against its ESG aspiration of achieving Gender Parity at all levels, reaching 40% of the Executive Leadership Team and 38% of senior leadership in 2023
- Continued to analyze pay equity; data shows the Company has no statistically significant gender pay gaps.
- Committed to the Living Wage Pledge and embarked on the journey to ensure all our employees around the world receive a living wage as defined within their country.
- Continued to pursue equitable representation in Leadership Development programs.
- Piloted Ignite your Impact, a program designed to help women navigate some of the unique challenges they face in leadership.
- Launched Mentor@IFF, IFF’s enterprise-wide mentoring program.
- Launched products through IFF Health that are helping women navigate the symptoms of menopause.
- Increased spending with women suppliers by 13% in our Supplier Diversity efforts.
-
Supported women in the communities in which we work:
- In the LMR Serbian platform, IFF supported women's entrepreneurship, providing access to alternative income streams by empowering women to manage their own beehives and make honey to sell to local markets.
- In the guar program in India, objectives included improving knowledge and support devices for women's empowerment. The project started in 2021, and since then, IFF has provided training to 230+ farmers and community members on the topic of women’s empowerment, highlighting the importance of women’s role in the field. IFF also provided 200 women farmers with farming tools to aid their work.
“While we are proud of this recognition and our progress, we recognize there’s much more to do,” said Borg. “In 2024, we will continue our partnership with EDGE—which has been instrumental in our efforts over the years—to advance equity at IFF. We will undergo EDGE Certification in all countries with 200 or more employees.”
To learn more about IFF’s leading Diversity, Equity and Inclusion efforts, visit here.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
© 2024 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229914819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
